-
[show abstract]
[hide abstract]
ABSTRACT: The understanding of radiotracer's physiological biodistribution as well as the potential source of false-positive results is crucial for an accurate diagnostic interpretation of F-fluorocholine PET/CT examination in patients with prostate cancer. We illustrate the results of whole-body F-fluorocholine PET/CT in a 79-year-old man with biochemical suspicion of prostate adenocarcinoma relapse. PET/CT study showed a focally increased F-fluorocholine uptake, characterizing an incidentally found adrenocortical adenoma. Finally, we draw oncologists' attention to the possible false-positive results of F-fluorocholine PET related to benign and unsuspected adrenocortical lesions in patients with a history of prostate malignancy.
Clinical nuclear medicine 02/2013; 38(2):e83-e84. · 3.92 Impact Factor
-
European Journal of Nuclear Medicine 08/2012; 39(10):1662-3. · 4.53 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Nuclear medicine imaging is a powerful diagnostic tool for the management of patients with gastro-entero-pancreatic neuroendocrine tumors, mainly developed considering some cellular characteristics that are specific to the neuroendocrine phenotype. Hence, overexpression of specific trans membrane receptors as well as the cellular ability to take up, accumulate, and decarboxylate amine precursors have been considered for diagnostic radiotracer development. Moreover, the glycolytic metabolism, which is not a specific energetic pathway of neuroendocrine tumors, has been proposed for radionuclide imaging of neuroendocrine tumors. The results of scintigraphic examinations reflect the pathologic features and tumor metabolic properties, allowing the in vivo characterization of the disease. In this article, the influence of both cellular differentiation and tumor grade in the scintigraphic pattern is reviewed according to the literature data. The relationship between nuclear imaging results and prognosis is also discussed. Despite the existence of a relationship between the results of scintigraphic imaging and cellular differentiation, tumor grade and patient outcome, the mechanism explaining the variability of the results needs further investigation.
Cancer Imaging 01/2012; 12:173-84. · 1.50 Impact Factor
-
Clinical nuclear medicine 06/2010; 35(6):434-7. · 3.92 Impact Factor
